Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 7/20 | 0.64 |
| ▸ | PSMB2 | P49721 | 7/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23797295 | 0.88 | TNF (0.52) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL16432070 | 0.88 | TNF (0.52) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL16432480 | 0.79 | TNF (0.45) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL23781066 | 0.79 | TNF (0.45) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL16328854 | 0.78 | TNF (0.53) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL6189205 | 0.78 | TNF (0.74) | TNFPSMB2PSMB5PSMB1 | |
| SCHEMBL19675236 | 0.77 | TNF (0.49) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL28039279 | 0.77 | TNF (0.49) | TNFPSMB2PSMB5PSMB1KDM4E | |
| SCHEMBL9393331 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23729375 | 0.73 | HTR2A (0.41) | TNFPSMB5PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009029214-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090054434-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-1994027969-A1 | ISOQUINOLINETRIONE DERIVATIVES AS HERBICIDES | ZENECA LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054434-A1 | ISOQUINOLONE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE5A, PDE4A, PDE4B | TNF 2097/4885PSMB2 3788/4885PSMB5 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.